# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-30T10:53:23.746105

---

**Idea Fidelity**

The paper largely follows the idea described in the manifest. It uses ClinicalTrials.gov data, exploits the FDAAA 801 phase exemption, and implements a DiD comparing Phase 2/3 (treated) with Phase 1 (control) trials, focusing on results posting as the main outcome and exploring outcome pre-specification as well. The sample period (2003–2015) and data source (REST API) align with the initial plan. One key deviation is that the manifest promised multiple outcomes—including outcome switching and time-to-results—whereas the paper focuses almost exclusively on the binary results-posted measure (plus the number of primary outcomes). The manifest’s pre-analysis plan also mentioned a second “dose” from the 2017 Final Rule, but the paper ends in 2015, leaving that variation unexplored. These omissions do not invalidate the exercise, but the paper should clarify that the identification focus is narrowed to the initial mandate and explain why the additional outcomes were omitted (data limitations, scope, etc.).

**Summary**

This paper studies the transparency effects of FDAAA 801 by comparing reporting behavior between exempt Phase 1 trials and mandated Phase 2/3 trials surrounding the 2007 reform. Using a DiD framework on ClinicalTrials.gov data from 2003–2015, it documents a 10 percentage point increase in results posting among mandated trials, driven entirely by industry-sponsored and U.S.-site trials. It also finds that the mandate is associated with fewer pre-specified primary outcomes and highlights differential pre-trends that complicate causal interpretation.

**Essential Points**

1. **Parallel Trends and Control Group Validity.** The placebo test reveals a strong and statistically significant pre-trend: Phase 2/3 reporting rates were already diverging from Phase 1 before FDAAA 801. This undermines the key DiD assumption. While the author acknowledges this in the discussion, the paper still reports the pooled estimate as the headline result. To make causal claims credible, the paper must either (a) model and account for the diverging trends (e.g., by allowing phase-specific linear pre-trends or estimating synthetic controls), or (b) focus the main causal interpretation on comparisons less likely to violate the assumption (e.g., within-industry versus non-industry if pre-trends there are parallel) and relegate the pooled estimate to a descriptive association. At minimum, the paper should include pre-trend tests separately by subgroups and transparently assess whether the heterogeneity analysis rests on a stronger identifying assumption.

2. **Mechanism Interpretation Requires Care.** The substantial heterogeneity by sponsor type/geography is interpreted as evidence of enforcement driving compliance, but the underlying causal channel is not fully pinned down. It remains possible that industry trials simply had stronger incentives to publish regardless of FDAAA (e.g., due to financial stakes or existing internal policies); Phase 2/3 industry trials may also have experienced other concurrent reforms (e.g., ICH E6 compliance) that differentially affected them. Similarly, the decrease in the number of primary outcomes could arise from compositional shifts rather than disciplined pre-specification. The paper needs to provide additional empirical checks or narrative reasoning to show that these patterns reflect the mandate/enforcement rather than other unobserved, industry-specific trends.

3. **Inference with Few Clusters and Weighting.** Standard errors are clustered by start year (13 clusters) yet several tables report statistically significant estimates without acknowledging the limited number of clusters or presenting wild bootstrap p-values. Some heterogeneity results (e.g., industry effect) rely on relatively small samples (e.g., 34,919 trials subdivided further). The paper should either present inference that is valid with few clusters (wild bootstrap, as mentioned) in the main tables or move to trial-level robust methods (e.g., trial-by-start-year fixed effects with permutation inference). Without this, the statistical significance (and the magnitude) of the estimates is hard to judge.

If these issues cannot be adequately addressed, the paper’s causal claims hinge on contentious assumptions, and stronger redesigns (e.g., alternative control groups or instrumental variables) may be required before acceptance.

**Suggestions**

1. **Addressing Parallel Trends Directly.**  
   - Present phase-specific pre-trends graphically with confidence intervals (event study) for both industry and non-industry samples. If the pre-trend divergence is confined to a subset (e.g., non-industry), note it explicitly.  
   - Consider augmenting the DiD with phase-by-year trends in the pre-period (e.g., allow each phase to have its own linear time trend estimated from pre-2007 data and extrapolate). This would help isolate the jump at the reform from the secular diverging trajectory.  
   - Alternatively, estimate models with matched Phase 1 controls—e.g., match Phase 2/3 trials to Phase 1 trials on baseline characteristics (enrollment, therapeutic area, sponsor type) and re-estimate the DiD within matched pairs to reduce flexibility in the counterfactual trajectory.

2. **Engaging More with the 2017 Final Rule (Second Dose).**  
   - The manifest promised exploiting both FDAAA 801 (2007) and the stronger enforcement under the 2017 Final Rule. If data permit, extend the sample to post-2017 or reframe the question around differential effects before/after the Final Rule for FDA-regulated trials with results due after 2017.  
   - Even if the paper cannot extend the sample (because of data freshness), explicitly state why (e.g., concerns about recent data completeness), and highlight how the planned second dose could be an avenue for future work.

3. **Clarify Mechanism Interpretation with Additional Outcomes.**  
   - Since the paper already has data on outcome pre-specification, consider supplementing it with other transparency metrics, such as time from completion to results posting, or the extent of result detail (primary vs. secondary outcomes posted). These additional margins could help disentangle enforcement-driven compliance versus compositional shifts.  
   - When interpreting the drop in primary outcomes, explore whether the mandate changed the distribution (e.g., medians, outliers) or the types of outcomes (binary vs. continuous). This could determine whether researchers simply chose fewer, better-defined outcomes or whether new trials were drafted differently.  
   - Examine whether the number of primary outcomes changed for Phase 1 trials after 2007—if not, that would support the idea that the observed change is mandate-driven rather than part of a broader trend.

4. **Robustness on Enforcement Channel.**  
   - To bolster the claim that enforcement drives the industry response, use variation in the FDA’s reliance on enforcement: for instance, compare trials that had FDA registries (FDA-regulated products) versus those that may be outside the FDA’s purview even within Phase 2/3 industry trials.  
   - Exploit administrative data on FDA inspections or penalty letters (if available) to show that treated industry trials with higher enforcement risk were more responsive.  
   - At a minimum, show that the industry vs. academic pre-trends were parallel to justify interpreting heterogeneity as causal.

5. **Inference and Presentation.**  
   - Include wild cluster bootstrap confidence intervals or p-values in the main regression tables (especially for the key phases and industry splits) to reassure readers about statistical significance with few clusters.  
   - Consider additional weighting schemes (e.g., weighting by trial-level inverse probability of being completed) if completion rates differ substantially across phases/time, to ensure the treatment effect isn’t driven by differential selection into completion.  
   - Report balance diagnostics (means of key covariates for Phase 1 vs. Phase 2/3, pre and post) in the appendix to support claims about compositional stability.

6. **Highlight Policy Implications with Guardrails.**  
   - Since the paper’s normative takeaway emphasizes enforcement, explicitly acknowledge limitations—e.g., the industry effect may reflect pre-existing FDA relationships—and caution against over-generalizing to other settings (like economics) without similar enforcement capacity.  
   - Suggest how future reforms (e.g., increasing penalties or expanding enforcement) could be evaluated using the same data, perhaps via discontinuities in enforcement intensity (e.g., certain therapeutic areas/policy checkpoints) rather than across phases.

In sum, the paper tackles an important question with a compelling dataset but needs to strengthen its identification story and mechanism interpretation. Addressing the above suggestions will clarify whether and how FDAAA 801 causally changed transparency in clinical trials.
